EP3026050A4 - Nouveau dérivé triazine - Google Patents

Nouveau dérivé triazine

Info

Publication number: EP3026050A4
Authority: EP; European Patent Office
Prior art keywords: triazine derivative; new triazine; new; derivative; triazine
Prior art date: 2013-07-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP14828654.5A

Other languages

German (de)

English (en)

Other versions

EP3026050A1 (fr

EP3026050B1 (fr

Inventor

Wataru Kawahata

Tokiko ASAMI

Masaaki Sawa

Yuko ASAMITSU

Takayuki Irie

Takahiro Miyake

Takao Kiyoi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Carna Biosciences Inc

Original Assignee

Carna Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-07-26

Filing date

2014-07-15

Publication date

2016-12-14

2014-07-15 Application filed by Carna Biosciences Inc filed Critical Carna Biosciences Inc

2016-06-01 Publication of EP3026050A1 publication Critical patent/EP3026050A1/fr

2016-12-14 Publication of EP3026050A4 publication Critical patent/EP3026050A4/fr

2018-11-07 Application granted granted Critical

2018-11-07 Publication of EP3026050B1 publication Critical patent/EP3026050B1/fr

Status Active legal-status Critical Current

2034-07-15 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

EP14828654.5A 2013-07-26 2014-07-15 Nouveau dérivé triazine Active EP3026050B1 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP2013155331		2013-07-26
JP2013187987		2013-09-11
JP2014073227		2014-03-31
PCT/JP2014/068752 WO2015012149A1 (fr)	2013-07-26	2014-07-15	Nouveau dérivé triazine

Publications (3)

Publication Number	Publication Date
EP3026050A1 EP3026050A1 (fr)	2016-06-01
EP3026050A4 true EP3026050A4 (fr)	2016-12-14
EP3026050B1 EP3026050B1 (fr)	2018-11-07

Family

ID=52393193

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP14828654.5A Active EP3026050B1 (fr)	2013-07-26	2014-07-15	Nouveau dérivé triazine

Country Status (15)

Country	Link
US (1)	US9656995B2 (fr)
EP (1)	EP3026050B1 (fr)
JP (1)	JP6156953B2 (fr)
KR (1)	KR101742550B1 (fr)
CN (1)	CN105683178B (fr)
AU (1)	AU2014294225B2 (fr)
CA (1)	CA2919068C (fr)
CR (1)	CR20160082A (fr)
DK (1)	DK3026050T3 (fr)
ES (1)	ES2699452T3 (fr)
IL (1)	IL243737B (fr)
NO (1)	NO20160292A1 (fr)
PH (1)	PH12016500152A1 (fr)
SG (1)	SG11201600497VA (fr)
WO (1)	WO2015012149A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2925177A1 (fr) *	2013-09-20	2015-03-26	Carna Biosciences, Inc.	Derive de triazine d'un nouveau type
EP3546462B1 (fr) *	2016-11-25	2024-01-03	Carna Biosciences, Inc.	Nouveau dérivé d'oxoisoquinoline
WO2021157650A1 (fr)	2020-02-05	2021-08-12	カルナバイオサイエンス株式会社	Composition d'agent anticancéreux
WO2022034914A1 (fr) *	2020-08-13	2022-02-17	カルナバイオサイエンス株式会社	Préparation pharmaceutique solide facilement soluble et son procédé de production
JPWO2022102715A1 (fr) *	2020-11-13	2022-05-19
WO2024245578A1 (fr)	2023-06-02	2024-12-05	Netherlands Translational Research Center Holding B.V.	Combinaisons thérapeutiques d'un inhibiteur de btk irréversible et d'un inhibiteur de btk réversible macrocyclique
WO2024245577A1 (fr)	2023-06-02	2024-12-05	Netherlands Translational Research Center Holding B.V.	Combinaisons thérapeutiques d'un inhibiteur irréversible de btk et d'un inhibiteur réversible de btk

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2300459T3 (pl) *	2008-07-02	2013-10-31	Hoffmann La Roche	Nowe fenylopirazynony jako inhibitory kinazy
US8299077B2 (en) *	2009-03-02	2012-10-30	Roche Palo Alto Llc	Inhibitors of Bruton's tyrosine kinase
PE20140865A1 (es)	2011-08-17	2014-07-19	Hoffmann La Roche	Inhibidores de la tirosina-quinasa de bruton
JP5832664B2 (ja) *	2011-12-09	2015-12-16	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ブルトン型チロシンキナーゼの阻害剤
EP2824099A4 (fr) *	2012-03-09	2015-11-11	Carna Biosciences Inc	Nouveau dérivé de triazine
WO2013161848A1 (fr) *	2012-04-27	2013-10-31	カルナバイオサイエンス株式会社	Nouveau dérivé de 1,2,4-triazine

2014
- 2014-07-15 KR KR1020167004910A patent/KR101742550B1/ko active Active
- 2014-07-15 DK DK14828654.5T patent/DK3026050T3/en active
- 2014-07-15 AU AU2014294225A patent/AU2014294225B2/en active Active
- 2014-07-15 CN CN201480051531.1A patent/CN105683178B/zh active Active
- 2014-07-15 JP JP2015528238A patent/JP6156953B2/ja active Active
- 2014-07-15 US US14/907,396 patent/US9656995B2/en active Active
- 2014-07-15 EP EP14828654.5A patent/EP3026050B1/fr active Active
- 2014-07-15 SG SG11201600497VA patent/SG11201600497VA/en unknown
- 2014-07-15 WO PCT/JP2014/068752 patent/WO2015012149A1/fr not_active Ceased
- 2014-07-15 CA CA2919068A patent/CA2919068C/fr active Active
- 2014-07-15 ES ES14828654T patent/ES2699452T3/es active Active
2016
- 2016-01-22 PH PH12016500152A patent/PH12016500152A1/en unknown
- 2016-01-24 IL IL243737A patent/IL243737B/en active IP Right Grant
- 2016-02-18 CR CR20160082A patent/CR20160082A/es not_active Application Discontinuation
- 2016-02-19 NO NO20160292A patent/NO20160292A1/en not_active Application Discontinuation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number	Publication date
IL243737B (en)	2019-09-26
ES2699452T3 (es)	2019-02-11
CR20160082A (es)	2016-06-08
IL243737A0 (en)	2016-04-21
JP6156953B2 (ja)	2017-07-05
JPWO2015012149A1 (ja)	2017-03-02
KR101742550B1 (ko)	2017-06-01
AU2014294225A1 (en)	2016-03-03
CA2919068A1 (fr)	2015-01-29
KR20160041946A (ko)	2016-04-18
DK3026050T3 (en)	2019-02-18
WO2015012149A1 (fr)	2015-01-29
US9656995B2 (en)	2017-05-23
CA2919068C (fr)	2018-03-20
PH12016500152A1 (en)	2016-04-25
NO20160292A1 (en)	2016-02-19
EP3026050A1 (fr)	2016-06-01
EP3026050B1 (fr)	2018-11-07
CN105683178A (zh)	2016-06-15
SG11201600497VA (en)	2016-02-26
CN105683178B (zh)	2019-04-12
US20160168122A1 (en)	2016-06-16
AU2014294225B2 (en)	2017-02-23

Publication	Publication Date	Title
EP2824099A4 (fr)	2015-11-11	Nouveau dérivé de triazine
EP2963037A4 (fr)	2016-08-03	Nouveau dérivé de pyrazole
DK3026045T3 (da)	2019-01-02	Quinolinderivat
LT3689865T (lt)	2023-07-10	Nauji aminopirimidinų dariniai
LT3060041T (lt)	2021-03-25	Prostaciklino junginiai
DK2970336T3 (da)	2017-11-13	Tetrahydropyrrolothiazinforbindelser
HRP20171890T1 (hr)	2018-01-12	Supstituirani imidazopiridazini
BR112015026261A2 (pt)	2017-07-25	derivados biaromáticos antibacterianos
DK2956698T3 (da)	2021-02-08	Bindestrimler
DK2952513T3 (da)	2019-09-02	Azolbenzenderivat
PL2945641T3 (pl)	2020-06-15	Cykloalkinowe pochodne sacharydów
DK2946640T3 (da)	2017-11-20	Langmuir-probe
EP3026050A4 (fr)	2016-12-14	Nouveau dérivé triazine
DE102013106534B8 (de)	2015-06-18	Chromatographiepipettenspitze
IL240904A0 (en)	2015-10-29	Azetidinyloxyphenylpyrrolidine compounds
HRP20190133T1 (hr)	2019-03-22	Heterociklički spoj
HRP20180618T1 (hr)	2018-07-13	Spojevi fluorfenilpirazola
DE112014001252A5 (de)	2016-01-21	Aufbissschiene
DK2947066T3 (da)	2019-01-02	Phenoxyalkylaminforbindelse
EP3009444A4 (fr)	2016-11-30	Dérivé alpha-oxoacyl amino-caprolactam
IL244664A0 (en)	2016-04-21	A new derivative of triazine
DK2999795T3 (da)	2019-08-26	Regulerbar genekspression
HRP20180722T1 (hr)	2018-06-15	Spoj benzotiofena
ITMI20130606A1 (it)	2014-10-13	Composti naftoeterodiazolici disostituiti
TH1401007086A (th)	2016-05-19	อนุพันธ์อัลริลเอทธินิล

Legal Events

Date	Code	Title	Description
2016-04-29	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-06-01	17P	Request for examination filed	Effective date: 20160223
2016-06-01	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2016-06-01	AX	Request for extension of the european patent	Extension state: BA ME
2016-12-14	A4	Supplementary search report drawn up and despatched	Effective date: 20161115
2016-12-14	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 37/02 20060101ALI20161109BHEP Ipc: A61K 31/53 20060101ALI20161109BHEP Ipc: A61P 37/08 20060101ALI20161109BHEP Ipc: A61P 35/02 20060101ALI20161109BHEP Ipc: C07D 401/14 20060101AFI20161109BHEP Ipc: A61P 35/00 20060101ALI20161109BHEP
2017-12-22	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2018-01-24	17Q	First examination report despatched	Effective date: 20180103
2018-05-21	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2018-05-21	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2018-06-20	INTG	Intention to grant announced	Effective date: 20180522
2018-09-29	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2018-10-05	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2018-10-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2018-11-07	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2018-11-07	AX	Request for extension of the european patent	Extension state: BA ME
2018-11-07	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2018-11-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP Ref country code: CH Ref legal event code: NV Representative=s name: BOVARD AG PATENT- UND MARKENANWAELTE, CH Ref country code: AT Ref legal event code: REF Ref document number: 1061915 Country of ref document: AT Kind code of ref document: T Effective date: 20181115
2018-11-29	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602014035716 Country of ref document: DE
2018-12-12	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2019-02-11	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2699452 Country of ref document: ES Kind code of ref document: T3 Effective date: 20190211
2019-02-18	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3 Effective date: 20190211
2019-02-26	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR
2019-03-20	REG	Reference to a national code	Ref country code: NL Ref legal event code: FP
2019-03-25	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2019-04-15	REG	Reference to a national code	Ref country code: NO Ref legal event code: T2 Effective date: 20181107
2019-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190307 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181107 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181107 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190207 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181107
2019-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190307 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181107 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181107 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190208
2019-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181107 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181107
2019-08-08	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602014035716 Country of ref document: DE
2019-08-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181107 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181107 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181107 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181107
2019-09-13	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2019-09-13	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2019-10-16	26N	No opposition filed	Effective date: 20190808
2019-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181107
2020-02-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: UEP Ref document number: 1061915 Country of ref document: AT Kind code of ref document: T Effective date: 20181107
2020-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181107
2020-03-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181107
2020-05-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190715
2021-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181107
2021-07-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20140715 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181107
2022-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181107
2023-06-28	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230522
2025-07-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20250529 Year of fee payment: 12
2025-07-14	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NO Payment date: 20250523 Year of fee payment: 12
2025-07-15	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: BE Payment date: 20250611 Year of fee payment: 12 Ref country code: IT Payment date: 20250526 Year of fee payment: 12
2025-07-18	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20250526 Year of fee payment: 12
2025-07-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IE Payment date: 20250522 Year of fee payment: 12
2025-07-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SE Payment date: 20250528 Year of fee payment: 12
2025-08-18	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NL Payment date: 20250726 Year of fee payment: 12
2025-10-09	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FI Payment date: 20250725 Year of fee payment: 12 Ref country code: ES Payment date: 20250801 Year of fee payment: 12
2025-10-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DK Payment date: 20250725 Year of fee payment: 12 Ref country code: DE Payment date: 20250731 Year of fee payment: 12
2025-10-20	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: AT Payment date: 20250709 Year of fee payment: 12
2025-10-21	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20250801 Year of fee payment: 12